Advanced Oncotherapy Regulatory News (AVO)

20 January 2015

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Establishment of CERN Scientific Review Board

Advanced Oncotherapy (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces that it has formed an external CERN Scientific Review Board to provide the Company with high-level scientific and engineering guidance as it develops and commercialises its LIGHT proton therapy system.

The CERN Scientific Review Board brings together distinguished thought leaders and global experts in the fields of physics, engineering and science. Alongside the Medical Advisory Board, which is focused on clinical outcomes, this committee will provide the Company management with invaluable advice from highly recognised experts as they develop and deliver a new game-changing technology in the proton radiation treatment arena.

Positions on the CERN Scientific Review Board are non-stipendiary and the founding members are listed below:

· Dr Stephen Myers (chair)- Head of CERN Medical Applications and the former Director of Accelerators and Technology at CERN. Dr Myers has been elected as a fellow of the Royal Academy of Engineering which honours the UK's most eminent engineers. He is internationally recognised for his engineering contributions and leadership in the development of CERN's particle colliders over the past 40 years, including the Intersecting Storage Rings, the Large Electron-Positron collider and the Large Hadron Collider.

· Dr Paul Collier - Head of the Beams Department at CERN. Dr Collier was project leader for the design study for the conversion of the Super Proton Synchrotron accelerator, and was crucially involved in the design of the injectors for the Large Hadron Collider. He is presently responsible for the operation and exploitation of all CERN accelerators including the Large Hadron Collider.

· Dr Erk Jensen - Head of the CERN Radio Frequency Group. Dr Jensen has been involved with the design and development of some of the most complex machines at CERN that rely on many branches of engineering, including mechanical, electrical and informatics.

· Professor Hanne Kooy - Head of Proton and Medical Physics at Harvard and the Massachusetts General Hospital. His interests lie in the effective deployment of the appropriate, advanced and integrated technologies to support proton radiation therapy.

· Ms Donatella Ungaro - Group Managing Director of Advanced Oncotherapy. Ms Ungaro was hired by CERN in 2005, where she was awarded the CERN Fellowship position in the Technical Coordination Group of the CMS experiment, which is one of the two general-purpose particle physics detectors built on the Large Hadron Collider and which discovered the Higgs' boson. She then joined Advanced Oncotherapy (ADAM) in 2008.

· Dr. Sanjeev Pandya - Chief Executive Officer of Advanced Oncotherapy.

Commenting, Sanjeev Pandya, CEO of Advanced Oncotherapy, said: "Advanced Oncotherapy's collaboration with CERN is our flagship venture. The advice we will receive from this newly formed committee will give us the opportunity to develop and commercialise, within our stated timeline, our ground-breaking proton therapy system; technology that we believe will offer clinical advantages at significantly less capital outlay than machines powered by cyclotrons and synchrotrons.

My colleagues and I are incredibly grateful for the support we have from some of the world's leading experts in acceleration technology and their dedication to make the LIGHT proton therapy system a success."

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy's team based at CERN in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.